BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 32719353)

  • 1. Can fewer transperineal systematic biopsy cores have the same prostate cancer detection rate as of magnetic resonance imaging/ultrasound fusion biopsy?
    Liu H; Ruan M; Wang H; Wang H; Li X; Song G
    Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):589-595. PubMed ID: 32719353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinically significant prostate cancer (csPCa) detection with various prostate sampling schemes based on different csPCa definitions.
    Wang F; Chen T; Wang M; Chen H; Wang C; Liu P; Liu S; Luo J; Ma Q; Xu L
    BMC Urol; 2021 Dec; 21(1):183. PubMed ID: 34949183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel sampling scheme with reduced cores in men with multiparametric MRI-visible lesions undergoing prostate biopsy.
    Ruan M; Wang H; Li X; Song G
    Abdom Radiol (NY); 2023 Jun; 48(6):2139-2147. PubMed ID: 37036488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of free-hand transperineal mpMRI/TRUS fusion-guided biopsy with transperineal 12-core systematic biopsy for the diagnosis of prostate cancer: a single-center prospective study in China.
    Zhang Q; Wang W; Zhang B; Shi J; Fu Y; Li D; Guo S; Zhang S; Huang H; Jiang X; Zhou W; Guo H
    Int Urol Nephrol; 2017 Mar; 49(3):439-448. PubMed ID: 28005230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of systematic prostate biopsies when performing transperineal MRI/TRUS fusion biopsy with needle tracking-what is the additional value?
    Günzel K; Magheli A; Busch J; Baco E; Cash H; Heinrich S; Edler D; Schostak M; Borgmann H; Schlegel J; Hinz S
    Int Urol Nephrol; 2022 Oct; 54(10):2477-2483. PubMed ID: 35877030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic performance of MRI/TRUS fusion-guided biopsies vs. systematic prostate biopsies in biopsy-naïve, previous negative biopsy patients and men undergoing active surveillance.
    Borghesi M; Bianchi L; Barbaresi U; Vagnoni V; Corcioni B; Gaudiano C; Fiorentino M; Giunchi F; Chessa F; Garofalo M; Bertaccini A; Angelini S; Ercolino A; Casablanca C; Droghetti M; Golfieri R; Schiavina R
    Minerva Urol Nephrol; 2021 Jun; 73(3):357-366. PubMed ID: 33769008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Magnetic Resonance Imaging (MRI)-Targeted Biopsy in Patients with Prostate-Specific Antigen (PSA) Levels <20 ng/mL: A Single-Center Study in Northeastern China.
    Dai Z; Liu Y; Huangfu Z; Wang L; Liu Z
    Med Sci Monit; 2021 Aug; 27():e930234. PubMed ID: 34365459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted Biopsy With Reduced Number of Cores: Optimal Sampling Scheme in Patients Undergoing Magnetic Resonance Imaging/Transrectal Ultrasound Fusion Prostate Biopsy.
    Shen WW; Cui LG; Ran WQ; Sun Y; Jiang J; Pei XL; Chen W
    Ultrasound Med Biol; 2020 May; 46(5):1197-1207. PubMed ID: 32107089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of Significant Prostate Cancer Using Target Saturation in Transperineal Magnetic Resonance Imaging/Transrectal Ultrasonography-fusion Biopsy.
    Tschirdewahn S; Wiesenfarth M; Bonekamp D; Püllen L; Reis H; Panic A; Kesch C; Darr C; Heß J; Giganti F; Moore CM; Guberina N; Forsting M; Wetter A; Hadaschik B; Radtke JP
    Eur Urol Focus; 2021 Nov; 7(6):1300-1307. PubMed ID: 32660838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The FUTURE Trial: A Multicenter Randomised Controlled Trial on Target Biopsy Techniques Based on Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer in Patients with Prior Negative Biopsies.
    Wegelin O; Exterkate L; van der Leest M; Kummer JA; Vreuls W; de Bruin PC; Bosch JLHR; Barentsz JO; Somford DM; van Melick HHE
    Eur Urol; 2019 Apr; 75(4):582-590. PubMed ID: 30522912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is There Still a Need for Repeated Systematic Biopsies in Patients with Previous Negative Biopsies in the Era of Magnetic Resonance Imaging-targeted Biopsies of the Prostate?
    Exterkate L; Wegelin O; Barentsz JO; van der Leest MG; Kummer JA; Vreuls W; de Bruin PC; Bosch JLHR; van Melick HHE; Somford DM
    Eur Urol Oncol; 2020 Apr; 3(2):216-223. PubMed ID: 31239236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship Between Prebiopsy Multiparametric Magnetic Resonance Imaging (MRI), Biopsy Indication, and MRI-ultrasound Fusion-targeted Prostate Biopsy Outcomes.
    Meng X; Rosenkrantz AB; Mendhiratta N; Fenstermaker M; Huang R; Wysock JS; Bjurlin MA; Marshall S; Deng FM; Zhou M; Melamed J; Huang WC; Lepor H; Taneja SS
    Eur Urol; 2016 Mar; 69(3):512-7. PubMed ID: 26112001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is targeted magnetic resonance imaging/transrectal ultrasound fusion prostate biopsy enough for the detection of prostate cancer in patients with PI-RADS ≥3: Results of a prospective, randomized clinical trial.
    Zhang J; Zhu A; Sun D; Guo S; Zhang H; Liu S; Fu Q; Zhang K
    J Cancer Res Ther; 2020; 16(7):1698-1702. PubMed ID: 33565519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimising the number of cores for magnetic resonance imaging-guided targeted and systematic transperineal prostate biopsy.
    Hansen NL; Barrett T; Lloyd T; Warren A; Samel C; Bratt O; Kastner C
    BJU Int; 2020 Feb; 125(2):260-269. PubMed ID: 31306539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Additional value of magnetic resonance-targeted biopsies to standard transrectal ultrasound-guided biopsies for detection of clinically significant prostate cancer.
    von Below C; Wassberg C; Norberg M; Tolf A; Kullberg J; Ladjevardi S; Häggman M; Bill Axelson A; Ahlström H
    Scand J Urol; 2017 Apr; 51(2):107-113. PubMed ID: 28635568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of contrast-enhanced ultrasound targeted biopsy versus standard systematic biopsy for clinically significant prostate cancer detection: results of a prospective cohort study with 1024 patients.
    Yunkai Z; Yaqing C; Jun J; Tingyue Q; Weiyong L; Yuehong Q; Wenbin G; Lifeng W; Jun Q
    World J Urol; 2019 May; 37(5):805-811. PubMed ID: 30187133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Prospective Comparison of Transrectal Standard, Cognitive, Transperineal Fusion, and Mapping Prostate Biopsy for Cancer Detection.
    Petov V; Bazarkin A; Morozov A; Taratkin M; Ganzha T; Danilov S; Chernov Y; Chinenov D; Rzayev R; Suvorov A; Amosov A; Fajkovic H; Enikeev D; Krupinov G
    J Endourol; 2023 Aug; 37(8):940-947. PubMed ID: 37294206
    [No Abstract]   [Full Text] [Related]  

  • 18. How Many Targeted Biopsy Cores are Needed for Clinically Significant Prostate Cancer Detection during Transperineal Magnetic Resonance Imaging Ultrasound Fusion Biopsy?
    Song G; Ruan M; Wang H; Fan Y; He Q; Lin Z; Li X; Li P; Wang X; He Z; Zhou L
    J Urol; 2020 Dec; 204(6):1202-1208. PubMed ID: 32716686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the optimal strategy in men with a single unilateral suspicious lesion on MRI undergoing transperineal MRI/ultrasound fusion prostate biopsy.
    Yusim I; Mazor E; Frumkin E; Jabareen M; Hefer B; Elsaraya N; Li S; Rouvinov K; Novack V; Mabjeesh NJ
    Prostate; 2023 Sep; 83(13):1255-1262. PubMed ID: 37263774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of free-hand transperineal targeted prostate biopsy using multiparametric magnetic resonance imaging-transrectal ultrasound fusion in Chinese men with prior negative biopsy and elevated prostate-specific antigen.
    Lian H; Zhuang J; Wang W; Zhang B; Shi J; Li D; Fu Y; Jiang X; Zhou W; Guo H
    BMC Urol; 2017 Jul; 17(1):52. PubMed ID: 28679370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.